Expected to Significantly Reduce Losses in 2024
March 18, 2025
Source: drugdu
41
AIM Vaccine announced on the Hong Kong Stock Exchange in the morning of March 17 that it expects to significantly reduce losses in performance. It is expected to record unaudited revenue of between 1.25 billion and 1.3 billion during the reporting period, an increase of 60 million to 110 million from the previous year's revenue of 1.19 billion, an increase of 5% to 9%, and an unaudited net loss of between 250 million and 290 million yuan, a significant reduction of 1.66 billion to 1.7 billion from the previous year's net loss of 1.95 billion yuan, a reduction of 85% to 87%. The board of directors initially believes that the increase in revenue is mainly due to the increase in the company's hepatitis B vaccine revenue, and the reduction in comprehensive net losses is mainly due to the reduction in the amount of large asset impairment losses and the increase in revenue this year.
https://finance.eastmoney.com/a/202503173347194165.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- JSKN003 Receives Breakthrough Therapy Designation in China March 19, 2025
- Shapuaisi obtains drug registration certificate for tafluprost eye drops March 19, 2025
- Huiyu Pharmaceuticals Obtains Drug Registration Certificate for Melphalan Hydrochloride March 19, 2025
- Two drugs were included in the “Rare Disease Drug Development “Care Plan” March 19, 2025
- First proof, first installment! Two medical devices approved for market launch March 18, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
